Bright Minds Biosciences (DRUG) to Release Quarterly Earnings on Wednesday

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its earnings results on Wednesday, May 21st. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.09. On average, analysts expect Bright Minds Biosciences to post $-1 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bright Minds Biosciences Trading Down 3.1%

NASDAQ DRUG traded down $1.01 during trading on Monday, reaching $31.99. The company's stock had a trading volume of 31,581 shares, compared to its average volume of 824,611. The stock has a market capitalization of $225.34 million, a PE ratio of -188.17 and a beta of -5.32. The business has a 50-day moving average price of $32.77 and a 200-day moving average price of $36.59. Bright Minds Biosciences has a 1-year low of $0.93 and a 1-year high of $79.02.

Hedge Funds Weigh In On Bright Minds Biosciences

A hedge fund recently bought a new stake in Bright Minds Biosciences stock. Goldman Sachs Group Inc. bought a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 22,222 shares of the company's stock, valued at approximately $802,000. Goldman Sachs Group Inc. owned 0.32% of Bright Minds Biosciences at the end of the most recent quarter. 40.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $85.00 price target on shares of Bright Minds Biosciences in a research report on Wednesday, February 19th. Cantor Fitzgerald raised shares of Bright Minds Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. TD Cowen assumed coverage on shares of Bright Minds Biosciences in a research report on Tuesday, May 13th. They issued a "buy" rating on the stock. Chardan Capital assumed coverage on shares of Bright Minds Biosciences in a research report on Wednesday, May 7th. They issued a "buy" rating and a $80.00 price target on the stock. Finally, Piper Sandler started coverage on shares of Bright Minds Biosciences in a research report on Thursday, January 23rd. They issued an "overweight" rating and a $93.00 price target on the stock. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Bright Minds Biosciences has an average rating of "Buy" and a consensus price target of $83.25.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.